How do oral COPD treatments compare? - Takeaways - MDSpire

How do oral COPD treatments compare?

Investigators assessed new users of azithromycin and roflumilast with active COPD.

Share

1

Azithromycin may lower the risk of a first moderate or severe COPD exacerbation compared to roflumilast.
2

The study analyzed data from 22,054 patients who initiated maintenance treatment with azithromycin or roflumilast.
3

After matching, 7,550 patients were included, with a median follow-up of 88 days.
4

Azithromycin was associated with a 17% lower likelihood of a first moderate or severe exacerbation.
5

Study limitations included short follow-up, potential misclassification, and lack of safety outcome assessment.